Arrhythmmia Research Technology Inc. Announces Repurchase of Five Percent of Its Common Stock.Business Editors &Health/Medical Writers AUSTIN, Texas--(BUSINESS WIRE)--Jan. 24, 2000 Arrhythmia Research Technology Inc. (AMEX AMEX See: American Stock Exchange :HRT HRT abbr. hormone replacement therapy Hormone replacement therapy (HRT) Also called estrogen replacement therapy, this controversial treatment is used to relieve the discomforts of menopause. ) (&uot;ART&uot;) announced that it had acquired in excess of five percent (5%) of its Common Stock. ART has been purchasing its Common Stock in the open market for the last several months in the belief that its stock is undervalued Undervalued A stock or other security that is trading below its true value. Notes: The difficulty is knowing what the "true" value actually is. Analysts will usually recommend an undervalued stock with a strong buy rating. . ART sells equipment used in the cardiovascular field for diagnosing and treating patients with irregular heartbeat and irregular electrical conduction patterns of the heart and cardiac catheterization physiological monitoring systems. Proprietary product lines include the 1200 EPX EPX Enterprise Private Exchange (tm), LP-Pac Q(tm), PREDICTOR series and ECG ECG electrocardiogram. ECG abbr. 1. electrocardiogram 2. electrocardiograph ECG Also called an electrocardiogram, it records the electrical activity of the heart. silver/silver chloride-plated sensors. The Arrhythmia Research Technology Inc. Web site is located at http://www.arthrt.com. Forward-looking statements made herein are based on current expectations of the Company that involve a number of risks and uncertainties and should not be considered as guarantees of future performance. These statements are made under the Safe Harbor Provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The factors that could cause actual results to differ materially include: interruptions or cancellation of existing contracts, impact of competitive products and pricing, product demand and market acceptance, risks, the presence of competitors with greater financial resources than the Company, product development and commercialization risks and an inability to arrange additional debt or equity financing. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion